These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19433709)

  • 1. Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.
    Davuluri G; Espina V; Petricoin EF; Ross M; Deng J; Liotta LA; Glaser BM
    Arch Ophthalmol; 2009 May; 127(5):613-21. PubMed ID: 19433709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F; Eid Farah M; Melo GB
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].
    Meyer CH; Helb HM; Eter N
    Ophthalmologe; 2008 Feb; 105(2):125-38, 140-2. PubMed ID: 18256841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].
    Kook D; Wolf A; Neubauer AS; Haritoglou C; Priglinger SG; Kampik A; Ulbig MW
    Ophthalmologe; 2008 Feb; 105(2):158-64. PubMed ID: 17653552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
    Ronan SM; Yoganathan P; Chien FY; Corcóstegui IA; Blumenkranz MS; Deramo VA; Elner SG; Fastenberg DA; Johnson MW; López M; Mateo C; Moshfeghi DM; Navarro R; Rosenblatt BJ; Sanislo SR; Saxe SJ; Zacks DN
    Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
    el Matri L; Chebil A; Kort F; Bouraoui R; Baklouti K; Mghaieth F
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and Outcomes of Full-thickness Macular Hole Repair in Patients Receiving Anti-VEGF Injections for Neovascular Age-related Macular Degeneration.
    Ringeisen AL; Parke DW; Dev S
    Int Ophthalmol Clin; 2019; 59(1):127-135. PubMed ID: 30585922
    [No Abstract]   [Full Text] [Related]  

  • 10. Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection.
    Roh MI; Lim SJ; Ahn JM; Lim JB; Kwon OW
    Graefes Arch Clin Exp Ophthalmol; 2010 May; 248(5):635-40. PubMed ID: 19997926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.
    Beer PM; Wong SJ; Hammad AM; Falk NS; O'Malley MR; Khan S
    Retina; 2006 Oct; 26(8):871-6. PubMed ID: 17031285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitrectomy after anti-VEGF therapy for epiretinal membranes coincident with age-related subfoveal choroidal neovascularization.
    Luttrull JK; Spink C
    Ophthalmic Surg Lasers Imaging; 2008; 39(6):455-9. PubMed ID: 19065974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD].
    Schaal KB; Engler C; Schütt F; Scheuerle A; Dithmar S
    Ophthalmologe; 2008 Jun; 105(6):538-43. PubMed ID: 18299845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration.
    Holekamp NM; Bouck N; Volpert O
    Am J Ophthalmol; 2002 Aug; 134(2):220-7. PubMed ID: 12140029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular biology of choroidal neovascularization.
    Lu M; Adamis AP
    Ophthalmol Clin North Am; 2006 Sep; 19(3):323-34. PubMed ID: 16935207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R; Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.